Drug Misclassification and Medicaid Rebates: One Category, a Smaller Rebate Bill

Drug misclassification can leave Medicaid rebates unpaid when a manufacturer reports a brand drug as generic and pays the lower rebate. Medicaid loses money the manufacturer owes it. The approval history says one thing. The category sent to Medicaid says another. If you work on product data, government pricing or rebate reconciliation, you may see the decision behind that difference, including what happened when someone inside the company questioned it. A field in the product master can determine how much money stays with the manufacturer.

How Does Drug Misclassification Reduce Medicaid Rebates?

Drug misclassification reduces Medicaid rebates by putting a drug on a lower rebate formula. The Medicaid Drug Rebate Program uses manufacturer-reported product and pricing information to calculate rebates owed to states. The Centers for Medicare & Medicaid Services calculates a rebate amount per unit, states invoice manufacturers for drugs Medicaid paid for, and manufacturers remain responsible for paying the correct amount. The government depends on the company that owes the money to report the information that sets the bill.

The category field uses three letters:

• S means single-source drug. It falls within the innovator side of the rebate calculation.
• I means innovator multiple-source drug. Generic competition does not move it out of the innovator category.
• N means noninnovator multiple-source drug. The agency also uses this category for other drugs outside the single-source and innovator multiple-source categories.

The Food and Drug Administration approval pathway matters. A new drug application generally points to innovator treatment, while an abbreviated new drug application points to noninnovator treatment. An authorized generic can be a product approved as a brand drug and sold without the brand label. The commercial name on the package does not settle its Medicaid category.

The Centers for Medicare & Medicaid Services established a narrow exception process in 2016 for certain drugs approved under a new drug application to receive noninnovator treatment. An approved exception belongs in the classification history. So does its effective date. The exception did not erase the manufacturer’s obligation to report the proper innovator category for earlier periods.

The money difference is substantial. For most innovator drugs, the basic rebate per unit is the greater of 23.1% of average manufacturer price or the difference between average manufacturer price and Best Price. Certain clotting factors and drugs approved exclusively for pediatric indications have a lower minimum. Noninnovator drugs have a basic rebate of 13% of average manufacturer price.

Average manufacturer price reflects specified sales to wholesalers and retail community pharmacies. Best Price generally captures the lowest qualifying price available from the manufacturer. These are distinct inputs. The category decides which rebate formula applies to them.

Brand Drug Reported as Generic

A brand drug reported as generic could avoid the Medicaid inflation rebate during the period before generics became subject to that rebate. That made the classification worth more than the difference between the basic rebate percentages: it could also remove the additional rebate owed when a drug’s price rose faster than inflation.

The Department of Health and Human Services’ Office of Inspector General report explains the change. Before January 2017, only innovator products owed inflation-adjusted rebates. Beginning January 1, 2017, noninnovator drugs became subject to them too. An old generic classification and a current one therefore have different consequences for the inflation component.

Another change increased the stakes of the baseline calculation. The Centers for Medicare & Medicaid Services final-rule fact sheet confirms that the cap limiting total Medicaid rebates to 100% of average manufacturer price ended for rebate periods beginning January 1, 2024. A drug’s rebate can now exceed its average manufacturer price.

What the Inspector General Found Behind the Classification Field

The Office of Inspector General’s December 2017 review identified 885 potentially misclassified drugs associated with 54 manufacturers. The problem was concentrated: four manufacturers accounted for more than half of the potential misclassifications.

The direction of the mismatch mattered. Of the potentially misclassified drugs, 97% appeared as noninnovator products in the Medicaid file but as innovator products in Food and Drug Administration data. Those classifications pointed toward lower basic rebates and, during the period examined, missed inflation rebates.

For the ten potentially misclassified drugs with the highest Medicaid reimbursement in 2016, the Office of Inspector General estimated $1.3 billion in additional rebates that manufacturers may have owed from 2012 through 2016. Most of that estimated shortfall, 90%, concerned just two drugs. All ten appeared as noninnovator products in the Medicaid file and innovator products in the approval data.

The force of the finding is the concentration: a small group of products could leave a very large rebate bill unpaid.

The oversight finding was just as revealing. The Office of Inspector General reported that the Centers for Medicare & Medicaid Services lacked a central database tracking potential classification errors and their resolution. The agency could identify a problem without being able to give the inspectors a complete account of what happened to it. The later correction rules address that gap directly.

EpiPen and Dava Put the Underpayment Into a Case

Mylan agreed to a $465 million settlement in August 2017 over allegations that it underpaid Medicaid rebates for EpiPen. The Justice Department’s announcement alleged that Mylan reported EpiPen as generic despite the absence of any therapeutically equivalent drug.

According to the department, between 2010 and 2016 Mylan increased EpiPen’s price by approximately 400% while paying only a fixed 13% rebate to Medicaid. The alleged classification let the company demand large price increases in the private market while avoiding the corresponding Medicaid rebate obligations. The price rose. The rebate stayed on the generic formula.

A competing manufacturer, Sanofi-Aventis US LLC, brought the whistleblower case. Its announced share of the federal recovery was approximately $38.7 million. Product knowledge can sit outside the company making the report, too.

Dava Pharmaceuticals had already agreed to an $11 million settlement in February 2012. The department described allegations of underpaid Medicaid rebates through drug classification and price reporting. That case also began as a qui tam case. The recurring issue is the connection between product information, reported prices and the rebate actually paid.

Why the Price and the Rebate Need Separate Attention

A study of U.S. branded drugs from 2015 through 2018 found that increases in estimated rebates were associated with increases in list prices. The USC Schaeffer Center’s 2020 paper, The Association Between Drug Rebates and List Prices, also found a stronger relationship for drugs without generic competition:

The study measured the gap between list prices and estimated net prices, including concessions across the distribution system.

What the Drug Misclassification Rule Requires

The Centers for Medicare & Medicaid Services final rule published in September 2024, effective November 19, 2024, reaches more than a brand drug reported as generic. It covers certified category or product information that the rules do not support. It also covers correctly reported information followed by rebate payments at a different level from the reported classification.

After the agency notifies a manufacturer of a misclassification, the manufacturer generally has 30 calendar days to supply the information needed for correction and certify the corrected data. It has 60 calendar days from notification to pay the unpaid rebates and document those payments to the agency.

If a manufacturer leaves the problem unresolved after notice, the agency can correct the data, impose penalties or suspend the drug from the rebate program. The rule also requires an annual public report identifying misclassified drugs and steps taken to correct them and recover unpaid rebates.

Earlier Quarters Still Matter

Correcting the category for future quarters leaves the earlier rebate bill to be addressed. The agency expressly states that unpaid rebates caused by misclassification are not limited to the previous 12 quarters.

The Market Date Can Change the Inflation Bill

The market date helps establish the base-date average manufacturer price used in the inflation rebate. Under the final rule, market date means the date the drug was first sold by any manufacturer. Acquiring a drug from another company does not restart that history.

The Acthar case shows why the baseline deserves attention alongside the category. In its March 2022 resolution, Mallinckrodt admitted that Acthar was not a new drug in 2013, had been approved and marketed before 1990, and agreed to correct its base-date average manufacturer price. The Justice Department described allegations that the later baseline avoided inflation rebates on earlier price increases.

The whistleblower’s amended complaint described what allegedly happened after the company calculated the liability:

That allegation puts the calculation and management’s response together. The product’s history explains the rebate. The internal discussion explains who understood the unpaid amount.

Where the Classification Error Travels

The 340B ceiling price uses average manufacturer price minus the Medicaid unit rebate amount. An understated rebate can therefore produce a higher ceiling price for safety-net purchasers. The same product data can affect both the money returned to Medicaid and the price a health center pays.

The rule also requires states to collect National Drug Codes and invoice rebates for all covered outpatient physician-administered drugs. For people reconciling claims and rebates, the product identifier connects what was administered to what the manufacturer owes.

What an Insider May Have

The useful evidence connects the product’s approval history, the certified report, the rebate calculation and the company’s response to a discrepancy. Manufacturers report product information in the Medicaid Drug Programs system and must certify changes there. The product master may contain the National Drug Code, S/I/N category, units per package, unit type, approval application, market date and base-date average manufacturer price. These are among the specific product fields the agency identifies in its rule.

Pricing workpapers and Best Price calculations explain the reported inputs. State invoices and payment records show the rebate paid. A CMS notice, internal liability calculation, certification or restatement can show when the issue became known and what the company did next. The strongest account follows the same product through those records.

This is where we work with an insider’s knowledge of the business. A category chosen during product setup, a market date inherited in an acquisition, or a correction applied only going forward each points to a different part of the rebate history. We connect those decisions to the amounts the government should have received and the people inside the business who understood them.

A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers.

When You Know Who Chose the Category

If you know why the approval record and the rebate report tell different stories, talk with our whistleblower experts about the category and the unpaid rebates. We work beside you to build the case around the product history, the money and the decisions that kept it unpaid. We bring in pharmaceutical fraud whistleblower lawyers who understand government pricing and Medicaid rebate cases, and stay with you through the process.